ArticleBJUI compass2025
Long non-coding RNAs define favourable biology in high-risk non-muscle-invasive bladder cancer.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long non-coding RNAs define favourable biology in high-risk non-muscle-invasive bladder cancer.BJUI compass · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate whether long non-coding RNA (lncRNA) expression patterns can improve molecular stratification and outcome prediction in high-risk non-muscle-invasive bladder cancer (NMIBC). Methods: RNA sequencing data from high-grade Ta (TaHG) and T1 (n = 212) tumours from the UROMOL consortium (Lindskrog et al., Nature Communications 2021) were analysed. Unsupervised consensus clustering based on lncRNA expression patterns identified distinct patient subgroups, which were characterized using gene expression patterns and gene signatures. A single-sample classifier was trained using elastic net logistic regression on UROMOL lncRNA expression profiles and applied to the Knowles cohort for independent validation. Recurrence-free survival (RFS) and progression-free survival (PFS) were evaluated using Kaplan-Meier (KM) plots, univariate and multivariate analyses. Results: LncRNA expression patterns identified three distinct clusters of TaHG and T1 tumours (LC1, LC2, LC3). Of these, the LC1 subgroup (n = 47) had significantly better RFS (p = 0.04) and PFS (p = 0.002). The LC1 subgroup was characterized by downregulation of genes associated with proliferation (i.e., Conclusion: LncRNA-based clustering demonstrates significant potential for improving patient stratification in high-risk NMIBC, identifying less aggressive tumours in an otherwise high-risk setting. A transcriptomic classifier trained on these findings was successfully validated in an independent cohort, supporting its potential clinical utility in refining risk assessment and guiding treatment decisions. Prospective studies are needed to further validate and refine this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.